Update Module 1533: The diagnosis and risks of rheumatoid arthritis - Chemist+Druggist

Update Module 1533: The diagnosis and risks of rheumatoid arthritis Chemist+Druggist In clinical practice, the final diagnosis of RA is based on careful consideration of all symptomatology, combined with blood test and imaging results. ...

Chelsea Therapeutics Questioned by FDA Over RA Drug - Pharmaceutical Processing

Chelsea Therapeutics Questioned by FDA Over RA Drug Pharmaceutical Processing Chelsea Therapeutics plans to test a 3-milligram dose in the upcoming trial, and said its drug may be safer and more effective than methotrexate, ... and more »

Chelsea Therapeutics will send RA drug data to FDA - BusinessWeek

Chelsea Therapeutics will send RA drug data to FDA BusinessWeek Chelsea Therapeutics International Ltd. said Tuesday it plans to give regulators more data in late July about a potential rheumatoid arthritis drug. ... Chelsea Therapeutics Initiates Northera Study 306 in Neurogenic Orthostatic ...MarketWatch (press release) all 27 news articles »

Gold Standard Diagnostics Signs Exclusive US Distribution Agreement with Axis ... - Business Wire (press release)

Gold Standard Diagnostics Signs Exclusive US Distribution Agreement with Axis ... Business Wire (press release) Axis-Shield owns a number of patents in the areas of cardiovascular and neurodegenerative diseases, rheumatoid arthritis, diabetes and more recently, ... and more »